212 related articles for article (PubMed ID: 24909372)
1. Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes.
Szabó M; Veres Z; Bátai-Konczos A; Kékesi O; Kis E; Szabó K; Jemnitz K
Toxicol In Vitro; 2014 Sep; 28(6):1136-43. PubMed ID: 24909372
[TBL] [Abstract][Full Text] [Related]
2. The hepatobiliary disposition of timosaponin b2 is highly dependent on influx/efflux transporters but not metabolism.
Sheng J; Tian X; Xu G; Wu Z; Chen C; Wang L; Pan L; Huang C; Pan G
Drug Metab Dispos; 2015 Jan; 43(1):63-72. PubMed ID: 25336752
[TBL] [Abstract][Full Text] [Related]
3. An experimental approach to evaluate the impact of impaired transport function on hepatobiliary drug disposition using Mrp2-deficient TR- rat sandwich-cultured hepatocytes in combination with Bcrp knockdown.
Yang K; Pfeifer ND; Hardwick RN; Yue W; Stewart PW; Brouwer KL
Mol Pharm; 2014 Mar; 11(3):766-75. PubMed ID: 24410402
[TBL] [Abstract][Full Text] [Related]
4. Comparative Hepatic and Intestinal Efflux Transport of Statins.
Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
[TBL] [Abstract][Full Text] [Related]
5. Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
Knauer MJ; Urquhart BL; Meyer zu Schwabedissen HE; Schwarz UI; Lemke CJ; Leake BF; Kim RB; Tirona RG
Circ Res; 2010 Feb; 106(2):297-306. PubMed ID: 19940267
[TBL] [Abstract][Full Text] [Related]
6. Not all statins interfere with clopidogrel during antiplatelet therapy.
Mach F; Senouf D; Fontana P; Boehlen F; Reber G; Daali Y; de Moerloose P; Sigwart U
Eur J Clin Invest; 2005 Aug; 35(8):476-81. PubMed ID: 16101667
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.
Bi YA; Qiu X; Rotter CJ; Kimoto E; Piotrowski M; Varma MV; Ei-Kattan AF; Lai Y
Biopharm Drug Dispos; 2013 Nov; 34(8):452-61. PubMed ID: 23996477
[TBL] [Abstract][Full Text] [Related]
8. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
Goard CA; Mather RG; Vinepal B; Clendening JW; Martirosyan A; Boutros PC; Sharom FJ; Penn LZ
Int J Cancer; 2010 Dec; 127(12):2936-48. PubMed ID: 21351272
[TBL] [Abstract][Full Text] [Related]
9. [Pleiotropic effects of statins].
Mennickent C S; Bravo D M; Calvo M C; Avello L M
Rev Med Chil; 2008 Jun; 136(6):775-82. PubMed ID: 18769836
[TBL] [Abstract][Full Text] [Related]
10. Regulation of multidrug resistance protein 2 (MRP2, ABCC2) expression by statins: involvement of SREBP-mediated gene regulation.
Kobayashi M; Gouda K; Chisaki I; Asada K; Ogura J; Takahashi N; Konishi T; Koshida Y; Sasaki S; Yamaguchi H; Iseki K
Int J Pharm; 2013 Aug; 452(1-2):36-41. PubMed ID: 23612356
[TBL] [Abstract][Full Text] [Related]
11. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.
Keppler D
Drug Metab Dispos; 2014 Apr; 42(4):561-5. PubMed ID: 24459177
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion.
Mayer C; Gruber HJ; Landl EM; Pailer S; Scharnagl H; Truschnig-Wilders M; März W
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):319-27. PubMed ID: 17595889
[TBL] [Abstract][Full Text] [Related]
14. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection.
Muchova L; Wong RJ; Hsu M; Morioka I; Vitek L; Zelenka J; Schröder H; Stevenson DK
Can J Physiol Pharmacol; 2007 Aug; 85(8):800-10. PubMed ID: 17901890
[TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
16. The clinical relevance of low-density-lipoproteins size modulation by statins.
Rizzo M; Berneis K
Cardiovasc Drugs Ther; 2006 Jun; 20(3):205-17. PubMed ID: 16775666
[TBL] [Abstract][Full Text] [Related]
17. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.
Varma MV; Rotter CJ; Chupka J; Whalen KM; Duignan DB; Feng B; Litchfield J; Goosen TC; El-Kattan AF
Mol Pharm; 2011 Aug; 8(4):1303-13. PubMed ID: 21710988
[TBL] [Abstract][Full Text] [Related]
18. Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes.
Jemnitz K; Veres Z; Tugyi R; Vereczkey L
Toxicol In Vitro; 2010 Mar; 24(2):605-10. PubMed ID: 19853032
[TBL] [Abstract][Full Text] [Related]
19. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
Li X; Zhong K; Guo Z; Zhong D; Chen X
Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
[TBL] [Abstract][Full Text] [Related]
20. Impact of statins on glucose metabolism--a matter of debate.
Anagnostis P; Athyros VG; Karagiannis A; Mikhailidis DP
Am J Cardiol; 2011 Jun; 107(12):1866. PubMed ID: 21640222
[No Abstract] [Full Text] [Related]
[Next] [New Search]
